SCHEMBL6032389

SCHEMBL6032389

O=c1ncoc2ncncc12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29587733 1.00
SCHEMBL16576781 0.71 FTO (0.38)
SCHEMBL29772429 0.70
SCHEMBL219450 0.70
SCHEMBL16742975 0.69
SCHEMBL913440 0.68 PDE5A (0.30)
SCHEMBL5258668 0.68 KDM4E (0.44)
SCHEMBL24624020 0.66 EGFR (0.31)
SCHEMBL8984128 0.65 EGFR (0.39)
SCHEMBL1704740 0.64 RPS6KA5 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3694509-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF Nuvation Bio Inc. (US) 2020-08-19 EP disclosed
WO-2019074981-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF GiraFpharma LLC (US) 2019-04-18 WO disclosed
EP-1631295-A2 USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER Arexis AB (SE) 2006-03-08 EP disclosed
WO-2004108139-A2 USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER AREXIS AB (SE) 2004-12-16 WO disclosed